

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10523603
Filing Date	2005-02-04
First Named Inventor	Hiroshi Kase
Art Unit	1617
Examiner Name	Sahar Javamard
Attorney Docket Number	00005.001205.1

U.S.PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	6346283		2002-02-12	Hoffman, et al.	Family member of WO 00/57894
	2	6544565		2003-04-08	Hoffman, et al.	Family member of WO 00/57894

If you wish to add additional U.S. Patent citation information please click the Add button.

[Add](#)

U.S.PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20020064569		2002-05-30	Hoffman et al.	Family member of WO 00/57894
	2	20040198753		2004-10-07	Kase et al.	Family member of WO 2003/063876
	3	20060148827		2006-07-06	Kase et al.	Family member of WO 2003/063876
	4	20060178379		2006-08-10	Kase et al.	Family member of WO 2003/063876

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10523603
Filing Date	2005-02-04
First Named Inventor	Hiroshi Kase
Art Unit	1617
Examiner Name	Sahar Javanmard
Attorney Docket Number	00005.001205.1

	5	20080176873		2008-07-24	Streeper et al.	
--	---	-------------	--	------------	-----------------	--

If you wish to add additional U.S. Published Application citation information please click the Add button

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No	Foreign Document Number ³	Country Code ² <i>i</i>	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	03/063876	WO		2003-08-07	Kase, et al.		<input type="checkbox"/>
	2	00/57894	WO		2000-10-05	Hoffman, et al.		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	MULLER, et al., "Interactions of valeren extracts and a fixed valeren - hop extract combination with adenosine receptors", Life Sciences, Vol. 71 (2002) 1939-49	<input type="checkbox"/>
	2	Radioligandbindungsstudien, Affinität verschiedener Baldrianextrakte zu A1-, A2A und A3-Adenosinrezeptoren, D3, 1-3	<input type="checkbox"/>
	3	Functional Studies, Adenosine-A2A-receptor-induced intracellular cAMP-accumulation und inhibition thereof, D4, 1-3	<input type="checkbox"/>
	4	ALLEN, ET AL., "Restless Legs Syndrome, A Review of Clinical and Pathophysiologic Features", Journal of Clinical Neurophysiology, Vol. 18, No. 2 (2001) 128-47	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10523603
Filing Date	2005-02-04
First Named Inventor	Hiroshi Kase
Art Unit	1617
Examiner Name	Sahar Javanmard
Attorney Docket Number	00005.001205.1

5	RICHARDSON, ET AL., "Adenosine A2A receptor antagonists as new agents for the treatment of Parkinson's disease", TIPS, Vol. 18 (1997) 338-44	<input type="checkbox"/>
6	SHIOZAKI, ET AL., "Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP", Psychopharmacology, Vol. 147 (1999) 90-5	<input type="checkbox"/>
7	MULLER, "A2A adenosine receptor antagonists - future drugs for Parkinson's disease", Drugs of the Future, Vol. 25, No. 10 (2000) 1043-52	<input type="checkbox"/>
8	EVIDENTE, ET AL., "Amantadine Is Beneficial in Restless Legs Syndrome", Movement Disorders, Vol. 15, No. 2 (2000) 324-27	<input type="checkbox"/>
9	ONDO, ET AL., "Exploring the Relationship Between Parkinson Disease and Restless Legs Syndrome", Arch. Neurol., Vol. 59 (2002) 421-24	<input type="checkbox"/>
10	MOREAU, ET AL., "Central adenosine A2A receptors: an overview", Brain Research Reviews, Vol. 31 (1999) 65-82	<input type="checkbox"/>
11	KASE, "New Aspects of Physiological and Pathophysiological Functions of Adenosine A2A Receptor in Basal Ganglia", Biosci. Biotechnol. Biochem., Vol. 65, No. 7 (2001) 1447-57	<input type="checkbox"/>
12	LUTZ, "Restless Legs, Anxiety and Caffeinism", J. Clin. Psychiatry, Vol. 39 (1978) 693-98	<input type="checkbox"/>
13	MULLER, ET AL., "Synthesis of Paraxanthine Analogs (1,7-Disubstituted Xanthines) and Other Xanthines ...", J. Med. Chem., Vol. 36 (1993) 3341-49	<input type="checkbox"/>
14	SLAWSKY, ET AL., "Ranolazine: a selective adenosine 1 receptor antagonist for the treatment of heart failure", Expert Opin. Pharmacother., Vol. 10, No. 2 (2009) 311-22	<input type="checkbox"/>
15	WALTHER, "Treating restless legs syndrome: current pathophysiological concepts and clinical trials", Expert Opin. Investig. Drugs, Vol. 11, No. 4 (2002) 501-14	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10523603
Filing Date	2005-02-04
First Named Inventor	Hiroshi Kase
Art Unit	1617
Examiner Name	Sahar Javanmard
Attorney Docket Number	00005.001205 1

16	MANCONI, "On the pathway of an animal model for restless legs syndrome", <i>Neurol. Sci.</i> , Vol. 28 (2007) S53-60	<input type="checkbox"/>
17	ASKENASY, "Approaching disturbed sleep in late Parkinson's Disease: first step toward a proposal for a revised UPDRS", <i>Parkinsonism and Related Disorders</i> , Vol 8 (2001) 123-31	<input type="checkbox"/>
18	Curriculum Vitae and a list of publications of Prof. C.E. Muller (17 pages)	<input type="checkbox"/>
19	Report on Comparative study on biotechnology patent practices, Theme: Comparative study on "reach-through claims" (2001) 1-19	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.